307 related articles for article (PubMed ID: 16636343)
1. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.
Wachter S; Tomek S; Kurtaran A; Wachter-Gerstner N; Djavan B; Becherer A; Mitterhauser M; Dobrozemsky G; Li S; Pötter R; Dudczak R; Kletter K
J Clin Oncol; 2006 Jun; 24(16):2513-9. PubMed ID: 16636343
[TBL] [Abstract][Full Text] [Related]
2. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
[TBL] [Abstract][Full Text] [Related]
3. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
[TBL] [Abstract][Full Text] [Related]
4. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
Vees H; Buchegger F; Albrecht S; Khan H; Husarik D; Zaidi H; Soloviev D; Hany TF; Miralbell R
BJU Int; 2007 Jun; 99(6):1415-20. PubMed ID: 17428249
[TBL] [Abstract][Full Text] [Related]
5. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy.
Reske SN; Blumstein NM; Glatting G
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):9-17. PubMed ID: 17828534
[TBL] [Abstract][Full Text] [Related]
6. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
[TBL] [Abstract][Full Text] [Related]
7. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging.
Giovacchini G; Picchio M; Briganti A; Cozzarini C; Scattoni V; Salonia A; Landoni C; Gianolli L; Di Muzio N; Rigatti P; Montorsi F; Messa C
J Urol; 2010 Sep; 184(3):938-43. PubMed ID: 20643445
[TBL] [Abstract][Full Text] [Related]
8. 11C-acetate positron-emission tomography/computed tomography imaging for detection of recurrent disease after radical prostatectomy or radiotherapy in patients with prostate cancer.
Esch LH; Fahlbusch M; Albers P; Hautzel H; Müller-Mattheis V
BJU Int; 2017 Sep; 120(3):337-342. PubMed ID: 27860163
[TBL] [Abstract][Full Text] [Related]
9. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?
Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H
Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339
[TBL] [Abstract][Full Text] [Related]
10. 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.
Yoshida S; Nakagomi K; Goto S; Futatsubashi M; Torizuka T
Urol Int; 2005; 74(3):214-20. PubMed ID: 15812206
[TBL] [Abstract][Full Text] [Related]
11. (11)C-acetate PET in the early evaluation of prostate cancer recurrence.
Albrecht S; Buchegger F; Soloviev D; Zaidi H; Vees H; Khan HG; Keller A; Bischof Delaloye A; Ratib O; Miralbell R
Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):185-96. PubMed ID: 16832632
[TBL] [Abstract][Full Text] [Related]
12. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.
Schöder H; Herrmann K; Gönen M; Hricak H; Eberhard S; Scardino P; Scher HI; Larson SM
Clin Cancer Res; 2005 Jul; 11(13):4761-9. PubMed ID: 16000572
[TBL] [Abstract][Full Text] [Related]
13. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.
Picchio M; Messa C; Landoni C; Gianolli L; Sironi S; Brioschi M; Matarrese M; Matei DV; De Cobelli F; Del Maschio A; Rocco F; Rigatti P; Fazio F
J Urol; 2003 Apr; 169(4):1337-40. PubMed ID: 12629355
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer.
Polanec SH; Andrzejewski P; Baltzer PAT; Helbich TH; Stiglbauer A; Georg D; Karanikas G; Susani M; Wadsak W; Margreiter M; Mitterhauser M; Brader P; Pinker K
PLoS One; 2017; 12(7):e0180790. PubMed ID: 28719629
[TBL] [Abstract][Full Text] [Related]
15. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy.
Hofer C; Laubenbacher C; Block T; Breul J; Hartung R; Schwaiger M
Eur Urol; 1999; 36(1):31-5. PubMed ID: 10364652
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.
Testa C; Schiavina R; Lodi R; Salizzoni E; Corti B; Farsad M; Kurhanewicz J; Manferrari F; Brunocilla E; Tonon C; Monetti N; Castellucci P; Fanti S; Coe M; Grigioni WF; Martorana G; Canini R; Barbiroli B
Radiology; 2007 Sep; 244(3):797-806. PubMed ID: 17652190
[TBL] [Abstract][Full Text] [Related]
17. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.
de Jong IJ; Pruim J; Elsinga PH; Vaalburg W; Mensink HJ
Eur Urol; 2003 Jul; 44(1):32-8; discussion 38-9. PubMed ID: 12814672
[TBL] [Abstract][Full Text] [Related]
18. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
[TBL] [Abstract][Full Text] [Related]
19. Value of bimodal (18)F-choline-PET/MRI and trimodal (18)F-choline-PET/MRI/TRUS for the assessment of prostate cancer recurrence after radiation therapy and radical prostatectomy.
Paparo F; Piccardo A; Bacigalupo L; Romagnoli A; Piccazzo R; Monticone M; Cevasco L; Campodonico F; Conzi GM; Carmignani G; Rollandi GA
Abdom Imaging; 2015 Aug; 40(6):1772-87. PubMed ID: 25579170
[TBL] [Abstract][Full Text] [Related]
20. [Pro and contra: 11C choline PET in diagnosis of prostate cancer].
Kotzerke J; Zöphel K; Salomon G; Graefen M; Heidenreich A
Aktuelle Urol; 2007 May; 38(3):189-94. PubMed ID: 17566231
[No Abstract] [Full Text] [Related]
[Next] [New Search]
